Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines
Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5–10% of healthy immunocompetent subjec...
Saved in:
| Published in | Journal of medical virology Vol. 78; no. 2; pp. 169 - 177 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.02.2006
Wiley-Liss |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5–10% of healthy immunocompetent subjects do not mount an antibody response (anti‐HBs). Non‐response is associated with different HLA‐DR alleles and impaired Th cell response, among other factors such as route of injection, age, gender, body mass, and other factors. Important hepatitis B surface antigen variants have also been identified, which may have a potential impact on immunization and routine screening of blood, blood products and tissues, and organs for transplantation. Strategies for hepatitis B immunization are reviewed. Over 1,000 million doses of hepatitis B vaccine have been used with an outstanding record of safety. There is no evidence of an association between hepatitis B vaccines and the sudden infant death syndrome, chronic fatigue syndrome, and multiple sclerosis (MS). Several studies are in progress on treatment of chronic hepatitis B infection by immunization with multiple antigenic components, combination of vaccine with antiviral drugs and cytokines, T cell vaccines, DNA vaccines alone or with DNA encoded immunomodulatory cytokines, and direct genetic manipulation of antigen presenting cells. J. Med. Virol. 78:169–177, 2006. © 2005 Wiley‐Liss, Inc. |
|---|---|
| AbstractList | Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5-10% of healthy immunocompetent subjects do not mount an antibody response (anti-HBs). Non-response is associated with different HLA-DR alleles and impaired Th cell response, among other factors such as route of injection, age, gender, body mass, and other factors. Important hepatitis B surface antigen variants have also been identified, which may have a potential impact on immunization and routine screening of blood, blood products and tissues, and organs for transplantation. Strategies for hepatitis B immunization are reviewed. Over 1,000 million doses of hepatitis B vaccine have been used with an outstanding record of safety. There is no evidence of an association between hepatitis B vaccines and the sudden infant death syndrome, chronic fatigue syndrome, and multiple sclerosis (MS). Several studies are in progress on treatment of chronic hepatitis B infection by immunization with multiple antigenic components, combination of vaccine with antiviral drugs and cytokines, T cell vaccines, DNA vaccines alone or with DNA encoded immunomodulatory cytokines, and direct genetic manipulation of antigen presenting cells. Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5–10% of healthy immunocompetent subjects do not mount an antibody response (anti‐HBs). Non‐response is associated with different HLA‐DR alleles and impaired Th cell response, among other factors such as route of injection, age, gender, body mass, and other factors. Important hepatitis B surface antigen variants have also been identified, which may have a potential impact on immunization and routine screening of blood, blood products and tissues, and organs for transplantation. Strategies for hepatitis B immunization are reviewed. Over 1,000 million doses of hepatitis B vaccine have been used with an outstanding record of safety. There is no evidence of an association between hepatitis B vaccines and the sudden infant death syndrome, chronic fatigue syndrome, and multiple sclerosis (MS). Several studies are in progress on treatment of chronic hepatitis B infection by immunization with multiple antigenic components, combination of vaccine with antiviral drugs and cytokines, T cell vaccines, DNA vaccines alone or with DNA encoded immunomodulatory cytokines, and direct genetic manipulation of antigen presenting cells. J. Med. Virol. 78:169–177, 2006. © 2005 Wiley‐Liss, Inc. Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5-10% of healthy immunocompetent subjects do not mount an antibody response (anti-HBs). Non-response is associated with different HLA-DR alleles and impaired Th cell response, among other factors such as route of injection, age, gender, body mass, and other factors. Important hepatitis B surface antigen variants have also been identified, which may have a potential impact on immunization and routine screening of blood, blood products and tissues, and organs for transplantation. Strategies for hepatitis B immunization are reviewed. Over 1,000 million doses of hepatitis B vaccine have been used with an outstanding record of safety. There is no evidence of an association between hepatitis B vaccines and the sudden infant death syndrome, chronic fatigue syndrome, and multiple sclerosis (MS). Several studies are in progress on treatment of chronic hepatitis B infection by immunization with multiple antigenic components, combination of vaccine with antiviral drugs and cytokines, T cell vaccines, DNA vaccines alone or with DNA encoded immunomodulatory cytokines, and direct genetic manipulation of antigen presenting cells. J. Med. Virol. 78:169-177, 2006. Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5-10% of healthy immunocompetent subjects do not mount an antibody response (anti-HBs). Non-response is associated with different HLA-DR alleles and impaired Th cell response, among other factors such as route of injection, age, gender, body mass, and other factors. Important hepatitis B surface antigen variants have also been identified, which may have a potential impact on immunization and routine screening of blood, blood products and tissues, and organs for transplantation. Strategies for hepatitis B immunization are reviewed. Over 1,000 million doses of hepatitis B vaccine have been used with an outstanding record of safety. There is no evidence of an association between hepatitis B vaccines and the sudden infant death syndrome, chronic fatigue syndrome, and multiple sclerosis (MS). Several studies are in progress on treatment of chronic hepatitis B infection by immunization with multiple antigenic components, combination of vaccine with antiviral drugs and cytokines, T cell vaccines, DNA vaccines alone or with DNA encoded immunomodulatory cytokines, and direct genetic manipulation of antigen presenting cells.Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5-10% of healthy immunocompetent subjects do not mount an antibody response (anti-HBs). Non-response is associated with different HLA-DR alleles and impaired Th cell response, among other factors such as route of injection, age, gender, body mass, and other factors. Important hepatitis B surface antigen variants have also been identified, which may have a potential impact on immunization and routine screening of blood, blood products and tissues, and organs for transplantation. Strategies for hepatitis B immunization are reviewed. Over 1,000 million doses of hepatitis B vaccine have been used with an outstanding record of safety. There is no evidence of an association between hepatitis B vaccines and the sudden infant death syndrome, chronic fatigue syndrome, and multiple sclerosis (MS). Several studies are in progress on treatment of chronic hepatitis B infection by immunization with multiple antigenic components, combination of vaccine with antiviral drugs and cytokines, T cell vaccines, DNA vaccines alone or with DNA encoded immunomodulatory cytokines, and direct genetic manipulation of antigen presenting cells. |
| Author | Zuckerman, Jane N. |
| Author_xml | – sequence: 1 givenname: Jane N. surname: Zuckerman fullname: Zuckerman, Jane N. email: j.zuckerman@medsch.ucl.ac.uk organization: Academic Centre for Travel Medicine and Vaccines and the WHO Collaborating Centre for Reference, Research and Training in Travel Medicine, Royal Free and University College Medical School, University College London, London, United Kingdom |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17551120$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16372285$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0ctu1DAUBmALFdFpYcELoGxAQmpa35MsaVXaouGqAhIb68RzorokTmo7A_P2zTBTKiEBK2--_9j-zx7Z8b1HQp4yesgo5UfX3fKQU8XlAzJjtNJ5RQu2Q2aUSZ1rzdQu2YvxmlJaVpw_IrtMi4LzUs3I5YfQJ7TJLTHDpnEW7Oogc103-j5dYYABx-RsNkzKJwftQQZ-kUVoMK2yvsmucIDkkovZcbYEa53H-Jg8bKCN-GR77pPPr08vT87z-fuzi5NX89xKzmXeIKuaUqEGXQPHWlnLhbT19LaFWBQSkaHQSqAEXQlWQsEAao6ysIJWTIp98mIzdwj9zYgxmc5Fi20LHvsxGl2oSjHN_wvX5ZWcreGzLRzrDhdmCK6DsDJ3hU3g-RZAtNA2Abx18d4VSjHG6eRebpwNfYwBm3tCzXppZlrar3vX3zj6w1qXplJ7nwK49l-JH67F1d9Hmzdvv9wl8k3CxYQ_fycgfJ9aEoUyX9-dmeKj_Hb8aX5uhLgFZdu2qg |
| CODEN | JMVIDB |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2019_01_056 crossref_primary_10_3389_fimmu_2023_1091237 crossref_primary_10_1016_j_vaccine_2009_09_069 crossref_primary_10_1016_S1473_3099_07_70136_6 crossref_primary_10_1080_21645515_2016_1250990 crossref_primary_10_1080_21645515_2016_1260794 crossref_primary_10_1128_JVI_01123_15 crossref_primary_10_3389_fimmu_2021_713351 crossref_primary_10_1016_j_vaccine_2018_07_072 crossref_primary_10_1371_journal_pone_0071124 crossref_primary_10_2298_MPNS0802055R crossref_primary_10_1186_s10020_021_00290_7 crossref_primary_10_1093_hmg_ddt586 crossref_primary_10_12968_denu_2022_49_1_26 crossref_primary_10_3390_v16111799 crossref_primary_10_1590_S0004_28032007000300003 crossref_primary_10_1146_annurev_pharmtox_061008_103129 crossref_primary_10_1016_j_cca_2011_01_030 crossref_primary_10_1371_journal_pone_0012273 crossref_primary_10_1016_j_vaccine_2019_11_067 crossref_primary_10_1039_C9RA06332C crossref_primary_10_1111_hdi_12326 crossref_primary_10_1016_j_scitotenv_2010_09_036 crossref_primary_10_1002_jmv_22251 crossref_primary_10_1016_j_vaccine_2016_11_041 crossref_primary_10_1086_587695 crossref_primary_10_1007_s11894_008_0016_9 crossref_primary_10_1186_s12879_021_06913_y crossref_primary_10_1542_peds_2011_2866 crossref_primary_10_1016_j_vaccine_2012_07_010 crossref_primary_10_23736_S2724_5276_19_05678_0 crossref_primary_10_1016_j_vaccine_2007_09_043 crossref_primary_10_1007_s12020_016_1061_z crossref_primary_10_1080_08916930701197273 crossref_primary_10_1016_j_ajg_2009_05_002 crossref_primary_10_1016_j_jhep_2012_11_036 crossref_primary_10_1007_s00430_014_0374_x crossref_primary_10_1007_s11908_009_0013_7 crossref_primary_10_1038_gene_2010_1 crossref_primary_10_1007_s00415_012_6716_y crossref_primary_10_1177_135965350701200409 crossref_primary_10_1080_15321819_2023_2168556 crossref_primary_10_3390_pathogens10101333 crossref_primary_10_1007_s00705_019_04369_9 crossref_primary_10_1517_14712598_2013_791277 crossref_primary_10_1002_hep_23543 crossref_primary_10_1586_erv_11_120 crossref_primary_10_1016_j_vaccine_2010_09_068 crossref_primary_10_4292_wjgpt_v12_i4_56 crossref_primary_10_1016_j_vaccine_2014_07_064 crossref_primary_10_1080_21645515_2018_1528835 crossref_primary_10_4254_wjh_v2_i3_136 crossref_primary_10_1016_j_vaccine_2010_07_068 crossref_primary_10_1111_j_1749_6632_2009_04800_x crossref_primary_10_1016_j_jcv_2018_04_014 crossref_primary_10_1016_j_vaccine_2008_10_043 crossref_primary_10_1586_14760584_6_4_527 crossref_primary_10_1007_s00430_010_0160_3 crossref_primary_10_1016_j_biologicals_2014_05_007 crossref_primary_10_1089_vim_2023_0121 crossref_primary_10_1016_j_vaccine_2019_08_036 crossref_primary_10_2298_SARH0802033R crossref_primary_10_1099_jmm_0_001274 crossref_primary_10_1111_jvh_13168 crossref_primary_10_4161_hv_29648 crossref_primary_10_1155_2016_5795712 crossref_primary_10_4292_wjg_v12_i4_56 crossref_primary_10_1016_j_vaccine_2014_09_042 crossref_primary_10_3390_pharmaceutics15051349 crossref_primary_10_1097_INF_0b013e3182345995 crossref_primary_10_1039_C6RA14419E crossref_primary_10_1002_eji_200635986 crossref_primary_10_1016_j_mayocpiqo_2020_06_007 crossref_primary_10_1016_j_vaccine_2017_03_021 crossref_primary_10_1128_CVI_00543_16 crossref_primary_10_1002_jmv_20816 crossref_primary_10_1016_j_vaccine_2007_12_044 crossref_primary_10_1016_j_pedneo_2015_07_003 crossref_primary_10_1016_j_pcl_2022_11_006 crossref_primary_10_1111_jvh_12649 crossref_primary_10_1016_j_vaccine_2016_02_050 crossref_primary_10_1007_s00467_013_2538_0 crossref_primary_10_1111_apt_16356 crossref_primary_10_1146_annurev_cellbio_100616_060718 crossref_primary_10_1080_21645515_2018_1450122 crossref_primary_10_2217_17460794_4_1_55 crossref_primary_10_3390_pathogens13090766 crossref_primary_10_1097_01_qco_0000244051_23511_09 crossref_primary_10_1186_s12879_024_09201_7 crossref_primary_10_4254_wjh_v8_i29_1212 crossref_primary_10_5812_jjm_91649 crossref_primary_10_1016_j_vaccine_2015_09_051 crossref_primary_10_1016_j_vaccine_2016_03_090 crossref_primary_10_1128_JVI_00200_10 crossref_primary_10_1007_s10405_014_0787_7 crossref_primary_10_1016_j_vaccine_2015_05_037 crossref_primary_10_1016_j_vaccine_2008_01_002 crossref_primary_10_2217_nnm_2017_0138 crossref_primary_10_1002_jmv_23658 crossref_primary_10_1016_j_vaccine_2007_10_044 crossref_primary_10_1136_bcr_2013_202191 crossref_primary_10_33631_duzcesbed_824589 crossref_primary_10_3892_mmr_2019_10231 crossref_primary_10_1016_j_vaccine_2013_06_108 crossref_primary_10_1016_j_jhep_2009_06_001 crossref_primary_10_1586_erv_09_97 crossref_primary_10_1080_21645515_2017_1283082 crossref_primary_10_1371_journal_pone_0002954 crossref_primary_10_1016_j_vaccine_2018_02_103 crossref_primary_10_1177_0734242X16649686 crossref_primary_10_1080_21645515_2020_1775457 crossref_primary_10_46563_1560_9561_2021_24_3_163_167 crossref_primary_10_1016_j_vaccine_2008_09_049 crossref_primary_10_18632_oncotarget_25789 crossref_primary_10_3109_10611860903450015 crossref_primary_10_3923_jpt_2016_27_32 crossref_primary_10_1038_nrneurol_2012_8 crossref_primary_10_1097_HJH_0b013e328012981b crossref_primary_10_5005_jp_journals_10018_1094 crossref_primary_10_1016_j_vaccine_2008_04_022 crossref_primary_10_1002_jmv_24756 crossref_primary_10_1007_s00115_009_2865_3 crossref_primary_10_3389_fimmu_2023_1122048 crossref_primary_10_21518_2079_701X_2017_4_47_51 crossref_primary_10_7717_peerj_4297 crossref_primary_10_1007_s11901_018_0435_5 crossref_primary_10_1111_jtm_12123 crossref_primary_10_1016_j_patbio_2009_03_004 crossref_primary_10_1016_j_vaccine_2008_03_051 crossref_primary_10_1371_journal_pone_0035303 crossref_primary_10_1016_j_coi_2006_05_004 crossref_primary_10_1590_S0037_86822007000200001 crossref_primary_10_1016_j_jcv_2011_05_016 crossref_primary_10_3389_fgene_2019_00696 crossref_primary_10_1016_j_jhep_2008_07_040 crossref_primary_10_1080_14760584_2017_1367667 crossref_primary_10_1590_S0036_46652010000500005 crossref_primary_10_5812_hepatmon_29325 crossref_primary_10_1542_peds_2021_055554 crossref_primary_10_1097_INF_0b013e318173966f crossref_primary_10_2105_AJPH_2011_300239 crossref_primary_10_5812_hepatmon_32799 crossref_primary_10_1080_21645515_2019_1680082 crossref_primary_10_3390_v15020313 crossref_primary_10_4049_jimmunol_1300293 crossref_primary_10_3892_mmr_2012_1079 crossref_primary_10_1111_jvh_13001 crossref_primary_10_1002_rmv_1942 |
| Cites_doi | 10.1002/jmv.2165 10.1212/01.WNL.0000138433.61870.82 10.1136/bmj.325.7364.569 10.1126/science.1100600 10.1016/S0264-410X(00)00461-8 10.1016/0264-410X(94)00080-7 10.1002/(SICI)1096-9071(199907)58:3<193::AID-JMV1>3.0.CO;2-X 10.1016/S0264-410X(98)00313-2 10.1586/14760584.1.2.141 10.1016/0140-6736(90)91874-A 10.1016/S0264-410X(01)00108-6 10.1016/j.virol.2004.04.042 10.1136/bmj.317.7152.159 10.1002/(SICI)1096-9071(199612)50:4<283::AID-JMV1>3.0.CO;2-4 10.1016/j.vaccine.2004.02.046 10.1002/rmv.359 10.1016/S0264-410X(98)00203-5 10.1212/WNL.53.2.396 10.1002/hep.510300208 10.1002/hep.510300511 10.1056/NEJM200102013440501 10.4049/jimmunol.137.1.315 10.1016/S0140-6736(03)14802-7 10.1084/jem.175.2.495 10.1016/S0140-6736(05)65950-8 10.1136/bmj.305.6862.1158 10.1002/jmv.10206 10.1056/NEJM198909143211103 10.1056/NEJM200102013440502 |
| ContentType | Journal Article |
| Copyright | Copyright © 2005 Wiley‐Liss, Inc. 2006 INIST-CNRS Copyright 2005 Wiley-Liss, Inc. |
| Copyright_xml | – notice: Copyright © 2005 Wiley‐Liss, Inc. – notice: 2006 INIST-CNRS – notice: Copyright 2005 Wiley-Liss, Inc. |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 |
| DOI | 10.1002/jmv.20524 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1096-9071 |
| EndPage | 177 |
| ExternalDocumentID | 16372285 17551120 10_1002_jmv_20524 JMV20524 ark_67375_WNG_7Q4ZBRLH_3 |
| Genre | article Journal Article Review |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WJL WNSPC WOHZO WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 |
| ID | FETCH-LOGICAL-c4224-fe19f85e6a6ba2eb5cc234cb372d3d74ee1e3653e4a69318a71aab2e47c309143 |
| IEDL.DBID | DR2 |
| ISSN | 0146-6615 |
| IngestDate | Fri Jul 11 04:33:55 EDT 2025 Fri Jul 11 10:13:58 EDT 2025 Wed Feb 19 01:46:27 EST 2025 Mon Jul 21 09:15:24 EDT 2025 Tue Jul 01 01:33:14 EDT 2025 Thu Apr 24 22:50:54 EDT 2025 Wed Jan 22 17:08:58 EST 2025 Wed Oct 30 09:55:28 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Immune response Toxicity Orthohepadnavirus Hepatic disease DNA vaccines Genetic vaccine Infection Virus Viral hepatitis B Hepadnaviridae Efficiency Viral disease Immunotherapy HBV mutants hepatitis B vaccines safety Digestive diseases Mutation Hepatitis B virus |
| Language | English |
| License | http://doi.wiley.com/10.1002/tdm_license_1.1 CC BY 4.0 Copyright 2005 Wiley-Liss, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4224-fe19f85e6a6ba2eb5cc234cb372d3d74ee1e3653e4a69318a71aab2e47c309143 |
| Notes | istex:06AF0235257C2686766D68E3D0B1BA1B762F23E2 ArticleID:JMV20524 ark:/67375/WNG-7Q4ZBRLH-3 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Review-3 |
| PMID | 16372285 |
| PQID | 20528212 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_67595162 proquest_miscellaneous_20528212 pubmed_primary_16372285 pascalfrancis_primary_17551120 crossref_primary_10_1002_jmv_20524 crossref_citationtrail_10_1002_jmv_20524 wiley_primary_10_1002_jmv_20524_JMV20524 istex_primary_ark_67375_WNG_7Q4ZBRLH_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2006 |
| PublicationDateYYYYMMDD | 2006-02-01 |
| PublicationDate_xml | – month: 02 year: 2006 text: February 2006 |
| PublicationDecade | 2000 |
| PublicationPlace | Hoboken |
| PublicationPlace_xml | – name: Hoboken – name: New York, NY – name: United States |
| PublicationTitle | Journal of medical virology |
| PublicationTitleAlternate | J. Med. Virol |
| PublicationYear | 2006 |
| Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
| Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
| References | Alper CA, Kruksall MS, Marcus_Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ. 1989. Genetic prediction of non-response to hepatitis B vaccine. New Eng J Med 321: 708-712. Beckebaum S, Cicinnati VR, Gerken G. 2002. DNA-based immunotherapy: Potential for the treatment of chronic viral hepatitis? Rev Med Virol 12: 297-319. Zuckerman AJ, Zuckerman JN. 1999. Molecular epidemiology of hepatitis B virus mutants. J Med Virol 58: 193-195. Zuckerman JN. 1996. Non-response to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 50: 283-288. Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. 2002. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 66: 452-460. WER. 1999. Expanded Programme on Immunisation (EPI). Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol Rec 72: 149-152. Francois G, Kew M, Van Damme P, Mphahled J, Meheus A. 2001. Mutant hepatitis B viruses: A matter of academic interest only or a problem with far-reaching implications? Vaccine 19: 3799-3815. Zuckerman JN, Zuckerman AJ. 2002. Recombinant hepatitis B triple antigen vaccine: Hepacare™. Expert Rev Vaccine 1: 141-144. Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, Margolis HS. 2002. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 68: 319-327. Oon C-J, Tan K-L, Harrison TJ, Zuckerman AJ. 1996. Natural history of hepatitis B surface antigen mutants in children. Lancet 348: 1524. Banatvala JE, Boxall E, Heptonstall J, Zuckerman AJ. 1996. Immunisation strategies: Proposal drafted in London and reviewed in prevention of hepatitis B in the newborn, children and adolescents. London: Royal Coll Physicians. pp 1-113. Heathcote J, McHutchinson J, Lee S, Tong M, Reener K, Minuk G, Wright T, Fikes J, Livingston B, Settie A, Chestnut R. 1999. A pilot study of the CY-T cell vaccine in subjects chronically infected with hepatitis B virus. The CY 1999 T Cell vaccine Study Group. Hepatology 30: 531-536. Hernan MA, Jick SS, Olek MJ, Jick H. 2004. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. Neurology 63: 838-842. Canada Communicable Disease Report. 1992. Adverse events following the administration of hepatitis B vaccines. Can Commun Dis Rep 18-7: 49-53. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. 1999. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30: 1312-1317. Oon C-J, Lim G-K, Zaho Y, Goh K-T, Tan K-L, Yo S-L, Hopes E, Harrison TJ, Zuckerman AJ. 1995. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13: 699-702. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336: 325-329. Jarrosson L, Kolopp-Sarda MN, Aguillar P, Bene MC, Faure GC, Kohler C. 2004. Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. Vaccine 22: 3789-3796. Jefferson T. 1998. Vaccination and its adverse effects: Real or perceived. Brit Med J 317: 159-160. Autram B, Carcelain G, Combadiere B, Debre P. 2004. Therapeutic vaccines for chronic infections. Science 305: 205-208. Gout O, Lyon-Caen O. 1998. Sclerotic plaques and vaccination against hepatitis B. Rev Neurol (Paris) 154: 205-207. Gonclaves L, Albarrar B, Salmen S, Borges L, Fields H, Montes H, Soyano A, Diaz Y, Berruta L. 2004. The non-response to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 326: 20-28. Canada Medical Association. 1993. Report of the working group on the possible relationship between hepatitis B vaccination and the chronic fatigue syndrome. Can Med Assoc J 149: 314-316. Zuckerman JN, Zuckerman AJ. 1998. Is there a need for boosters of hepatitis B vaccines? Viral Hepatitis Rev 4: 43-46. Zuckerman JN, Cockcroft A, Zuckerman AJ. 1992. Site of injection for vaccination. Brit Med J 305: 1158-1159. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. 2001. Vaccinations and the risk of relapse in multiple sclerosis. New Eng J Med 344: 319-326. Wilson JN, Nokes DJ, Carman WF. 1999. The predicted pattern of emergence of vaccine-resistant hepatitis B: A cause for concern? Vaccine 17: 973-978. Michel M-L, Pol S, Brechot C, Tiollais P. 2001. Immunotherapy of chronic hepatitis B by anti-HBV vaccine: From present to future. Vaccine 19: 2395-2399. Krusall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. 1992. The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. J Exp Med 175: 495-502. Wraith DC, Goldman M, Lambert P-H. 2003. Vaccination and autoimmune disease: What is the evidence? Lancet 362: 1659-1666. Ascherio A, Zhnag SM, Herbab MA, Olek MJ, Coplan PM, Brodovicz K, walker AM. 2001. Hepatitis B vaccination and the risk of multiple sclerosis. New Eng J Med 344: 327-332. European Consensus Group on Hepatitis B Immunity. 2002. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355: 561-565. Tourbah A, Gout O, Liblau R, Lyon-Caen O, Bougniot C, Iba-Zizen Cabanis EA. 1999. Encephalitis after hepatitis B vaccination: Recurrent disseminated encephalitis or MS? Neurology 53: 396-401. Milich DR, McLachlan A, Chisari FV, Kent SB, Thornton GB. 1986. Immune response to the pre-S1 region of hepatitis B surface antigen: A pre-S1-specific T cell response can bypass non-responsiveness to the pre-S2 and S regions of HbsAg. J Immunol 137: 315-322. Whittle H, Jaffar S, Warnsborough M, Mendy M, Dumpis U, Collinson A, Hall XX. 2002. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Brit Med J 325: 569-572. McDermott AB, Cohen SBA, Zuckerman JN, Madrigal J. 1999. Human leukocyte antigens influence the immune response to a pre-S1, pre-S2, S hepatitis B vaccine. Vaccine 17: 330-339. 2004; 22 2001; 344 2004; 63 1986; 137 2002; 12 2002; 355 1995; 13 1998; 317 1996; 50 2002; 1 1997 1996 1992; 305 1998; 154 2004; 305 1993; 149 2004; 326 1996; 348 1999 1990; 336 1992; 18‐7 1989; 321 1992; 175 1999; 17 2002; 68 2002; 66 1999; 58 2001; 19 2002; 325 1999; 53 1999; 30 1999; 72 1998; 4 2003; 362 1988 Heathcote (10.1002/jmv.20524-BIB16) 1999; 30 Canada Medical Association (10.1002/jmv.20524-BIB8) 1993; 149 Tourbah (10.1002/jmv.20524-BIB30) 1999; 53 Gout (10.1002/jmv.20524-BIB15) 1998; 154 Arif (10.1002/jmv.20524-BIB2) 1988 Beckebaum (10.1002/jmv.20524-BIB6) 2002; 12 Confavreux (10.1002/jmv.20524-BIB10) 2001; 344 Zuckerman (10.1002/jmv.20524-BIB38) 2002; 1 Canada Communicable Disease Report (10.1002/jmv.20524-BIB7) 1992; 18-7 Zuckerman (10.1002/jmv.20524-BIB36) 1998; 4 Banatvala (10.1002/jmv.20524-BIB5) 1996 European Consensus Group on Hepatitis B Immunity (10.1002/jmv.20524-BIB12) 2002; 355 Hsu (10.1002/jmv.20524-BIB18) 1999; 30 Jefferson (10.1002/jmv.20524-BIB20) 1998; 317 Margolis (10.1002/jmv.20524-BIB22) 1999 Nainan (10.1002/jmv.20524-BIB27) 2002; 68 Zuckerman (10.1002/jmv.20524-BIB37) 1999; 58 McDermott (10.1002/jmv.20524-BIB23) 1999; 17 Wraith (10.1002/jmv.20524-BIB34) 2003; 362 Alper (10.1002/jmv.20524-BIB1) 1989; 321 Hernan (10.1002/jmv.20524-BIB17) 2004; 63 Francois (10.1002/jmv.20524-BIB13) 2001; 19 Jarrosson (10.1002/jmv.20524-BIB19) 2004; 22 WER (10.1002/jmv.20524-BIB31) 1999; 72 Zuckerman (10.1002/jmv.20524-BIB35) 1996; 50 Carman (10.1002/jmv.20524-BIB9) 1990; 336 Krusall (10.1002/jmv.20524-BIB21) 1992; 175 Whittle (10.1002/jmv.20524-BIB32) 2002; 325 Gonclaves (10.1002/jmv.20524-BIB14) 2004; 326 Oon (10.1002/jmv.20524-BIB28) 1995; 13 Michel (10.1002/jmv.20524-BIB24) 2001; 19 Oon (10.1002/jmv.20524-BIB29) 1996; 348 Ascherio (10.1002/jmv.20524-BIB3) 2001; 344 Milich (10.1002/jmv.20524-BIB25) 1986; 137 Nainan (10.1002/jmv.20524-BIB26) 1997 Wilson (10.1002/jmv.20524-BIB33) 1999; 17 Zuckerman (10.1002/jmv.20524-BIB39) 1992; 305 Autram (10.1002/jmv.20524-BIB4) 2004; 305 Dahmen (10.1002/jmv.20524-BIB11) 2002; 66 |
| References_xml | – reference: Heathcote J, McHutchinson J, Lee S, Tong M, Reener K, Minuk G, Wright T, Fikes J, Livingston B, Settie A, Chestnut R. 1999. A pilot study of the CY-T cell vaccine in subjects chronically infected with hepatitis B virus. The CY 1999 T Cell vaccine Study Group. Hepatology 30: 531-536. – reference: Zuckerman JN. 1996. Non-response to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 50: 283-288. – reference: McDermott AB, Cohen SBA, Zuckerman JN, Madrigal J. 1999. Human leukocyte antigens influence the immune response to a pre-S1, pre-S2, S hepatitis B vaccine. Vaccine 17: 330-339. – reference: Wilson JN, Nokes DJ, Carman WF. 1999. The predicted pattern of emergence of vaccine-resistant hepatitis B: A cause for concern? Vaccine 17: 973-978. – reference: Francois G, Kew M, Van Damme P, Mphahled J, Meheus A. 2001. Mutant hepatitis B viruses: A matter of academic interest only or a problem with far-reaching implications? Vaccine 19: 3799-3815. – reference: Hernan MA, Jick SS, Olek MJ, Jick H. 2004. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. Neurology 63: 838-842. – reference: Zuckerman JN, Zuckerman AJ. 1998. Is there a need for boosters of hepatitis B vaccines? Viral Hepatitis Rev 4: 43-46. – reference: Banatvala JE, Boxall E, Heptonstall J, Zuckerman AJ. 1996. Immunisation strategies: Proposal drafted in London and reviewed in prevention of hepatitis B in the newborn, children and adolescents. London: Royal Coll Physicians. pp 1-113. – reference: Zuckerman AJ, Zuckerman JN. 1999. Molecular epidemiology of hepatitis B virus mutants. J Med Virol 58: 193-195. – reference: Whittle H, Jaffar S, Warnsborough M, Mendy M, Dumpis U, Collinson A, Hall XX. 2002. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Brit Med J 325: 569-572. – reference: Wraith DC, Goldman M, Lambert P-H. 2003. Vaccination and autoimmune disease: What is the evidence? Lancet 362: 1659-1666. – reference: Gout O, Lyon-Caen O. 1998. Sclerotic plaques and vaccination against hepatitis B. Rev Neurol (Paris) 154: 205-207. – reference: Oon C-J, Tan K-L, Harrison TJ, Zuckerman AJ. 1996. Natural history of hepatitis B surface antigen mutants in children. Lancet 348: 1524. – reference: Alper CA, Kruksall MS, Marcus_Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ. 1989. Genetic prediction of non-response to hepatitis B vaccine. New Eng J Med 321: 708-712. – reference: WER. 1999. Expanded Programme on Immunisation (EPI). Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol Rec 72: 149-152. – reference: Michel M-L, Pol S, Brechot C, Tiollais P. 2001. Immunotherapy of chronic hepatitis B by anti-HBV vaccine: From present to future. Vaccine 19: 2395-2399. – reference: Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. 2002. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 66: 452-460. – reference: Beckebaum S, Cicinnati VR, Gerken G. 2002. DNA-based immunotherapy: Potential for the treatment of chronic viral hepatitis? Rev Med Virol 12: 297-319. – reference: European Consensus Group on Hepatitis B Immunity. 2002. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355: 561-565. – reference: Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, Margolis HS. 2002. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 68: 319-327. – reference: Zuckerman JN, Zuckerman AJ. 2002. Recombinant hepatitis B triple antigen vaccine: Hepacare™. Expert Rev Vaccine 1: 141-144. – reference: Zuckerman JN, Cockcroft A, Zuckerman AJ. 1992. Site of injection for vaccination. Brit Med J 305: 1158-1159. – reference: Tourbah A, Gout O, Liblau R, Lyon-Caen O, Bougniot C, Iba-Zizen Cabanis EA. 1999. Encephalitis after hepatitis B vaccination: Recurrent disseminated encephalitis or MS? Neurology 53: 396-401. – reference: Krusall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. 1992. The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. J Exp Med 175: 495-502. – reference: Ascherio A, Zhnag SM, Herbab MA, Olek MJ, Coplan PM, Brodovicz K, walker AM. 2001. Hepatitis B vaccination and the risk of multiple sclerosis. New Eng J Med 344: 327-332. – reference: Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. 2001. Vaccinations and the risk of relapse in multiple sclerosis. New Eng J Med 344: 319-326. – reference: Canada Communicable Disease Report. 1992. Adverse events following the administration of hepatitis B vaccines. Can Commun Dis Rep 18-7: 49-53. – reference: Jarrosson L, Kolopp-Sarda MN, Aguillar P, Bene MC, Faure GC, Kohler C. 2004. Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. Vaccine 22: 3789-3796. – reference: Gonclaves L, Albarrar B, Salmen S, Borges L, Fields H, Montes H, Soyano A, Diaz Y, Berruta L. 2004. The non-response to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 326: 20-28. – reference: Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336: 325-329. – reference: Milich DR, McLachlan A, Chisari FV, Kent SB, Thornton GB. 1986. Immune response to the pre-S1 region of hepatitis B surface antigen: A pre-S1-specific T cell response can bypass non-responsiveness to the pre-S2 and S regions of HbsAg. J Immunol 137: 315-322. – reference: Autram B, Carcelain G, Combadiere B, Debre P. 2004. Therapeutic vaccines for chronic infections. Science 305: 205-208. – reference: Oon C-J, Lim G-K, Zaho Y, Goh K-T, Tan K-L, Yo S-L, Hopes E, Harrison TJ, Zuckerman AJ. 1995. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13: 699-702. – reference: Canada Medical Association. 1993. Report of the working group on the possible relationship between hepatitis B vaccination and the chronic fatigue syndrome. Can Med Assoc J 149: 314-316. – reference: Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. 1999. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30: 1312-1317. – reference: Jefferson T. 1998. Vaccination and its adverse effects: Real or perceived. Brit Med J 317: 159-160. – volume: 325 start-page: 569 year: 2002 end-page: 572 article-title: Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children publication-title: Brit Med J – volume: 19 start-page: 3799 year: 2001 end-page: 3815 article-title: Mutant hepatitis B viruses: A matter of academic interest only or a problem with far‐reaching implications? publication-title: Vaccine – volume: 66 start-page: 452 year: 2002 end-page: 460 article-title: Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin‐2 in patients with chronic hepatitis B publication-title: J Med Virol – volume: 326 start-page: 20 year: 2004 end-page: 28 article-title: The non‐response to hepatitis B vaccination is associated with impaired lymphocyte activation publication-title: Virology – volume: 22 start-page: 3789 year: 2004 end-page: 3796 article-title: Most humoral non‐responders to hepatitis B vaccines develop HBV‐specific cellular immune responses publication-title: Vaccine – volume: 58 start-page: 193 year: 1999 end-page: 195 article-title: Molecular epidemiology of hepatitis B virus mutants publication-title: J Med Virol – volume: 17 start-page: 330 year: 1999 end-page: 339 article-title: Human leukocyte antigens influence the immune response to a pre‐S1, pre‐S2, S hepatitis B vaccine publication-title: Vaccine – volume: 344 start-page: 319 year: 2001 end-page: 326 article-title: Vaccinations and the risk of relapse in multiple sclerosis publication-title: New Eng J Med – volume: 348 start-page: 1524 year: 1996 article-title: Natural history of hepatitis B surface antigen mutants in children publication-title: Lancet – volume: 321 start-page: 708 year: 1989 end-page: 712 article-title: Genetic prediction of non‐response to hepatitis B vaccine publication-title: New Eng J Med – volume: 68 start-page: 319 year: 2002 end-page: 327 article-title: Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection publication-title: J Med Virol – volume: 1 start-page: 141 year: 2002 end-page: 144 article-title: Recombinant hepatitis B triple antigen vaccine: Hepacare™ publication-title: Expert Rev Vaccine – volume: 355 start-page: 561 year: 2002 end-page: 565 article-title: Are booster immunisations needed for lifelong hepatitis B immunity? publication-title: Lancet – volume: 17 start-page: 973 year: 1999 end-page: 978 article-title: The predicted pattern of emergence of vaccine‐resistant hepatitis B: A cause for concern? publication-title: Vaccine – volume: 12 start-page: 297 year: 2002 end-page: 319 article-title: DNA‐based immunotherapy: Potential for the treatment of chronic viral hepatitis? publication-title: Rev Med Virol – volume: 175 start-page: 495 year: 1992 end-page: 502 article-title: The immune response to hepatitis B vaccine in humans: Inheritance patterns in families publication-title: J Exp Med – volume: 362 start-page: 1659 year: 2003 end-page: 1666 article-title: Vaccination and autoimmune disease: What is the evidence? publication-title: Lancet – volume: 305 start-page: 1158 year: 1992 end-page: 1159 article-title: Site of injection for vaccination publication-title: Brit Med J – start-page: 714 year: 1988 end-page: 716 – volume: 137 start-page: 315 year: 1986 end-page: 322 article-title: Immune response to the pre‐S1 region of hepatitis B surface antigen: A pre‐S1‐specific T cell response can bypass non‐responsiveness to the pre‐S2 and S regions of HbsAg publication-title: J Immunol – volume: 53 start-page: 396 year: 1999 end-page: 401 article-title: Encephalitis after hepatitis B vaccination: Recurrent disseminated encephalitis or MS? publication-title: Neurology – volume: 305 start-page: 205 year: 2004 end-page: 208 article-title: Therapeutic vaccines for chronic infections publication-title: Science – volume: 63 start-page: 838 year: 2004 end-page: 842 article-title: Recombinant hepatitis B vaccine and the risk of multiple sclerosis publication-title: Neurology – volume: 344 start-page: 327 year: 2001 end-page: 332 article-title: Hepatitis B vaccination and the risk of multiple sclerosis publication-title: New Eng J Med – start-page: 132 year: 1997 end-page: 134 – volume: 4 start-page: 43 year: 1998 end-page: 46 article-title: Is there a need for boosters of hepatitis B vaccines? publication-title: Viral Hepatitis Rev – volume: 50 start-page: 283 year: 1996 end-page: 288 article-title: Non‐response to hepatitis B vaccines and the kinetics of anti‐HBs production publication-title: J Med Virol – volume: 30 start-page: 1312 year: 1999 end-page: 1317 article-title: Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan publication-title: Hepatology – volume: 336 start-page: 325 year: 1990 end-page: 329 article-title: Vaccine‐induced escape mutant of hepatitis B virus publication-title: Lancet – volume: 317 start-page: 159 year: 1998 end-page: 160 article-title: Vaccination and its adverse effects: Real or perceived publication-title: Brit Med J – start-page: 1 year: 1996 end-page: 113 article-title: Immunisation strategies: Proposal drafted in London and reviewed in prevention of hepatitis B in the newborn, children and adolescents publication-title: London: Royal Coll Physicians – volume: 72 start-page: 149 year: 1999 end-page: 152 article-title: Expanded Programme on Immunisation (EPI). Lack of evidence that hepatitis B vaccine causes multiple sclerosis publication-title: Wkly Epidemiol Rec – volume: 149 start-page: 314 year: 1993 end-page: 316 article-title: Report of the working group on the possible relationship between hepatitis B vaccination and the chronic fatigue syndrome publication-title: Can Med Assoc J – volume: 19 start-page: 2395 year: 2001 end-page: 2399 article-title: Immunotherapy of chronic hepatitis B by anti‐HBV vaccine: From present to future publication-title: Vaccine – volume: 13 start-page: 699 year: 1995 end-page: 702 article-title: Molecular epidemiology of hepatitis B virus vaccine variants in Singapore publication-title: Vaccine – volume: 30 start-page: 531 year: 1999 end-page: 536 article-title: A pilot study of the CY‐T cell vaccine in subjects chronically infected with hepatitis B virus. The CY 1999 T Cell vaccine Study Group publication-title: Hepatology – volume: 18‐7 start-page: 49 year: 1992 end-page: 53 article-title: Adverse events following the administration of hepatitis B vaccines publication-title: Can Commun Dis Rep – volume: 154 start-page: 205 year: 1998 end-page: 207 article-title: Sclerotic plaques and vaccination against hepatitis B publication-title: Rev Neurol (Paris) – year: 1999 – volume: 66 start-page: 452 year: 2002 ident: 10.1002/jmv.20524-BIB11 publication-title: J Med Virol doi: 10.1002/jmv.2165 – volume: 63 start-page: 838 year: 2004 ident: 10.1002/jmv.20524-BIB17 publication-title: Neurology doi: 10.1212/01.WNL.0000138433.61870.82 – volume: 325 start-page: 569 year: 2002 ident: 10.1002/jmv.20524-BIB32 publication-title: Brit Med J doi: 10.1136/bmj.325.7364.569 – volume: 305 start-page: 205 year: 2004 ident: 10.1002/jmv.20524-BIB4 publication-title: Science doi: 10.1126/science.1100600 – volume: 19 start-page: 2395 year: 2001 ident: 10.1002/jmv.20524-BIB24 publication-title: Vaccine doi: 10.1016/S0264-410X(00)00461-8 – start-page: 132 volume-title: Viral Hepatitis and Liver Disease year: 1997 ident: 10.1002/jmv.20524-BIB26 – volume: 13 start-page: 699 year: 1995 ident: 10.1002/jmv.20524-BIB28 publication-title: Vaccine doi: 10.1016/0264-410X(94)00080-7 – volume: 58 start-page: 193 year: 1999 ident: 10.1002/jmv.20524-BIB37 publication-title: J Med Virol doi: 10.1002/(SICI)1096-9071(199907)58:3<193::AID-JMV1>3.0.CO;2-X – volume: 17 start-page: 973 year: 1999 ident: 10.1002/jmv.20524-BIB33 publication-title: Vaccine doi: 10.1016/S0264-410X(98)00313-2 – volume: 1 start-page: 141 year: 2002 ident: 10.1002/jmv.20524-BIB38 publication-title: Expert Rev Vaccine doi: 10.1586/14760584.1.2.141 – volume: 18-7 start-page: 49 year: 1992 ident: 10.1002/jmv.20524-BIB7 publication-title: Can Commun Dis Rep – volume: 336 start-page: 325 year: 1990 ident: 10.1002/jmv.20524-BIB9 publication-title: Lancet doi: 10.1016/0140-6736(90)91874-A – volume: 19 start-page: 3799 year: 2001 ident: 10.1002/jmv.20524-BIB13 publication-title: Vaccine doi: 10.1016/S0264-410X(01)00108-6 – volume: 326 start-page: 20 year: 2004 ident: 10.1002/jmv.20524-BIB14 publication-title: Virology doi: 10.1016/j.virol.2004.04.042 – volume: 317 start-page: 159 year: 1998 ident: 10.1002/jmv.20524-BIB20 publication-title: Brit Med J doi: 10.1136/bmj.317.7152.159 – volume: 50 start-page: 283 year: 1996 ident: 10.1002/jmv.20524-BIB35 publication-title: J Med Virol doi: 10.1002/(SICI)1096-9071(199612)50:4<283::AID-JMV1>3.0.CO;2-4 – volume: 22 start-page: 3789 year: 2004 ident: 10.1002/jmv.20524-BIB19 publication-title: Vaccine doi: 10.1016/j.vaccine.2004.02.046 – year: 1999 ident: 10.1002/jmv.20524-BIB22 – volume: 12 start-page: 297 year: 2002 ident: 10.1002/jmv.20524-BIB6 publication-title: Rev Med Virol doi: 10.1002/rmv.359 – volume: 17 start-page: 330 year: 1999 ident: 10.1002/jmv.20524-BIB23 publication-title: Vaccine doi: 10.1016/S0264-410X(98)00203-5 – volume: 72 start-page: 149 year: 1999 ident: 10.1002/jmv.20524-BIB31 publication-title: Wkly Epidemiol Rec – volume: 53 start-page: 396 year: 1999 ident: 10.1002/jmv.20524-BIB30 publication-title: Neurology doi: 10.1212/WNL.53.2.396 – volume: 355 start-page: 561 year: 2002 ident: 10.1002/jmv.20524-BIB12 publication-title: Lancet – volume: 30 start-page: 531 year: 1999 ident: 10.1002/jmv.20524-BIB16 publication-title: Hepatology doi: 10.1002/hep.510300208 – volume: 30 start-page: 1312 year: 1999 ident: 10.1002/jmv.20524-BIB18 publication-title: Hepatology doi: 10.1002/hep.510300511 – volume: 344 start-page: 319 year: 2001 ident: 10.1002/jmv.20524-BIB10 publication-title: New Eng J Med doi: 10.1056/NEJM200102013440501 – volume: 137 start-page: 315 year: 1986 ident: 10.1002/jmv.20524-BIB25 publication-title: J Immunol doi: 10.4049/jimmunol.137.1.315 – start-page: 714 volume-title: Viral hepatitis and liver disease year: 1988 ident: 10.1002/jmv.20524-BIB2 – volume: 154 start-page: 205 year: 1998 ident: 10.1002/jmv.20524-BIB15 publication-title: Rev Neurol (Paris) – volume: 362 start-page: 1659 year: 2003 ident: 10.1002/jmv.20524-BIB34 publication-title: Lancet doi: 10.1016/S0140-6736(03)14802-7 – start-page: 1 year: 1996 ident: 10.1002/jmv.20524-BIB5 publication-title: London: Royal Coll Physicians – volume: 175 start-page: 495 year: 1992 ident: 10.1002/jmv.20524-BIB21 publication-title: J Exp Med doi: 10.1084/jem.175.2.495 – volume: 348 start-page: 1524 year: 1996 ident: 10.1002/jmv.20524-BIB29 publication-title: Lancet doi: 10.1016/S0140-6736(05)65950-8 – volume: 149 start-page: 314 year: 1993 ident: 10.1002/jmv.20524-BIB8 publication-title: Can Med Assoc J – volume: 305 start-page: 1158 year: 1992 ident: 10.1002/jmv.20524-BIB39 publication-title: Brit Med J doi: 10.1136/bmj.305.6862.1158 – volume: 68 start-page: 319 year: 2002 ident: 10.1002/jmv.20524-BIB27 publication-title: J Med Virol doi: 10.1002/jmv.10206 – volume: 4 start-page: 43 year: 1998 ident: 10.1002/jmv.20524-BIB36 publication-title: Viral Hepatitis Rev – volume: 321 start-page: 708 year: 1989 ident: 10.1002/jmv.20524-BIB1 publication-title: New Eng J Med doi: 10.1056/NEJM198909143211103 – volume: 344 start-page: 327 year: 2001 ident: 10.1002/jmv.20524-BIB3 publication-title: New Eng J Med doi: 10.1056/NEJM200102013440502 |
| SSID | ssj0008922 |
| Score | 2.209104 |
| SecondaryResourceType | review_article |
| Snippet | Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral... |
| SourceID | proquest pubmed pascalfrancis crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 169 |
| SubjectTerms | Age Factors Alleles Biological and medical sciences DNA vaccines Fundamental and applied biological sciences. Psychology HBV mutants Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B Antibodies - blood Hepatitis B Surface Antigens hepatitis B vaccines Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - genetics Hepatitis B Vaccines - immunology Hepatitis B Vaccines - therapeutic use Hepatitis B, Chronic - therapy HLA-DR Antigens - genetics Human viral diseases Humans immune response immunotherapy Infectious diseases Injections Medical sciences Microbiology Miscellaneous Mutation Safety Sex Factors T-Lymphocytes, Helper-Inducer - immunology Vaccination Vaccines, DNA Viral diseases Viral hepatitis Virology |
| Title | Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines |
| URI | https://api.istex.fr/ark:/67375/WNG-7Q4ZBRLH-3/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.20524 https://www.ncbi.nlm.nih.gov/pubmed/16372285 https://www.proquest.com/docview/20528212 https://www.proquest.com/docview/67595162 |
| Volume | 78 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9UwFG8IJsYXvz-uCjbGGB8YbP3aFp7AiDdEiBJQYkya066LCO4StkvEv57T9u5er4HE-LaHsy7n9Hz8up7-SsgrSGWVKssTz6WeCGWzpCxMlaTWpSZjkJU2dPnuquGB2D6UhwtkvT8LE_khpj_cfGSEfO0DHEy7NiMN_fHzHJd3knkuUN-r5QHR3ow6qijjDgJmggRrkOxZhVK2Nn1zrhbd8Gb95XsjoUXz1PFei6uA5zyODYVo6w751qsQ-0-OV8edWbW__2J3_E8d75LbE4BKN6JH3SMLrrlPbu5MtuAfkP2PkdkBsyR1nn8C7MUKPfLHTP48zEVPUarB9HGyQqGpaAu16y7oqKbfnW_i7o5auknPwfpR24fkYOvd_tthMrmaIbECi35Su6ysC-kUKAPMGWkt48IanrOKV7lwLnM4J9wJUCWmDcgzAMOcyC1HhCL4I7LYjBr3hFCeMk9AY1kqQAhggJDE4DJKZLZSdQUD8qafJG0nvOX--owTHRmXmUYr6WClAXk5FT2NZB1XCb0OMz2VgLNj392WS_1l973OP4mvm3sfhpoPyPKcK8yGzKWHqemAvOh9Q2NQ-p0WaNxo3IYPFQgKrpfAdRpiW4USj6NTzUZXaERWSNQ7uMb1mujtnc_h4em_iz4jt-JPJN-Q85wsdmdjt4SwqjPLIX4uAcymHMY |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4amwS8cL-Uy2YhhHhYtsS3JBIvDDHKaCuYujEhIctxHDE20mlNJ8av59huWoo2CfGWhxNHPjmXz_bxdwCe61iUsTQsclzqEZcmifKsKKPY2LhIqE5y46t8B7K7x3cOxMESvGrvwgR-iNmGm_MMH6-dg7sN6c05a-j3H2e4vhOUX4EV19HbL6h25-RRWR7OEDAWRJiFRMsrFNPN2asL2WjFKfanq47UY1RQFTpbXAQ9F5GsT0XbN-FrO4lQgXK0MWmKDfPrL37H_53lLbgxxajkdTCq27Bk6ztwtT89hb8Lw4-B3AEDJbGOgkKb83Vy6G6a_Hmfi5ygVI0R5Hid6LokY13Z5pyMKvLNujru5nBMtsiZNm7U8T3Y2347fNONpt0ZIsMx70eVTfIqE1ZqWWhqC2EMZdwULKUlK1NubWKZFMxyLXOMHDpNtC6o5alhCFI4uw_L9ai2D4GwmDoOGkNjrjnXVCMqKXAlxRNTyqrUHXjZ_iVlptTlroPGsQqky1ShlpTXUgeezURPAl_HRUIv_K-eSejTI1fglgr1efBOpZ_4l63dXlexDqwu2MJ8yFQ4pBp3YK01DoV-6Q5bdG1Hk7H_UIa44HIJXKohvJUo8SBY1Xx0iUqkmcB5e9u4fCZqp7_vHx79u-gaXOsO-z3Vez_48Biuhz0lV5_zBJab04l9iiirKVa9M_0GgLIg4Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9RAFJ4gJMQX8YrrBSbGGB8otHNrG59EXFeEDRJQQkwmp9NpRKC7oV0i_nrPdLa7roHE-NaH02nOmXP5pnPmG0JeQijzUBkeOC71QCgTBWmS5UFobJhFDKLUNF2-fdU7FNtH8miOvGnPwnh-iMkPNxcZTb52AT7Mi40paeiP80tc3kkmbpEFocLEufTW_pQ7Kkn9FgKmggCLkGxphUK2MXl1phgtOLv-dM2RUKF9Cn-xxXXIcxbINpWou0S-tTr4BpTT9VGdrZtff9E7_qeSd8mdMUKlb71L3SNztrxPFnfHe_APyMGep3bANEmtI6AAc7VGT9w5kz9Pc9EhSpWYP87WKJQ5raCw9RUdFPS7dV3c9UlFN-klGDdq9ZAcdt8fvOsF47sZAiOw6geFjdIikVaByoDZTBrDuDAZj1nO81hYG1muJLcCVIp5A-IIIGNWxIYjRBH8EZkvB6V9TCgPmWOgMSwUIAQwQEyS4TpKRCZXRQ4d8rqdJG3GxOXu_owz7SmXmUYr6cZKHfJiIjr0bB3XCb1qZnoiARenrr0tlvpr_4OOP4vjzf2dnuYdsjLjCtMhY-lwatghq61vaIxKt9UCpR2MquZDCaKCmyVwoYbgVqHEsneq6egKjcgSiXo3rnGzJnp790vz8OTfRVfJ4t5WV-987H96Sm77H0quOecZma8vRvY5Qqw6W2lC6TcmRB-Z |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protective+efficacy%2C+immunotherapeutic+potential%2C+and+safety+of+hepatitis+B+vaccines&rft.jtitle=Journal+of+medical+virology&rft.au=Zuckerman%2C+Jane+N&rft.date=2006-02-01&rft.issn=0146-6615&rft.volume=78&rft.issue=2&rft.spage=169&rft_id=info:doi/10.1002%2Fjmv.20524&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |